Fisher Wallace Labs: Company Research Report
Company Overview
Name: Fisher Wallace Laboratories, Inc.
Mission of the Company: Fisher Wallace Labs is committed to increasing access to rapid and safe mental healthcare through the development, validation, and commercialization of wearable brain stimulation technology aimed at treating anxiety, depression, insomnia, and other neuropsychiatric and cognitive disorders.
Founded: No information is available.
Founders:
- Kelly Roman, Co-Founder, CEO, and Director
- Chip Fisher, Co-Founder, Chairman, and Director
Key People:
- Kelly Roman, Co-Founder, CEO, Director
- Chip Fisher, Co-Founder, Chairman, Director
- Simon Webster, Advisor
- Maurizio Fava, MD, Advisor
- David Shulkin, MD, Advisor
- Michael Greenberg, MD, MPH, FACEP, Medical Advisor
- Scott Witt, Advisor
- Neil Liebowitz, MD, JD, Advisor
Headquarters: 630 Flushing Avenue, Suite 104, Brooklyn, NY 11206
Number of Employees: No information is available.
Revenue of the Company: No information is available.
What is the Company Known For: The company is internationally recognized for pioneering wearable brain stimulation devices for mental healthcare, primarily targeting conditions such as anxiety, depression, and insomnia.
Products
OAK (Version 2.0 Wearable)
Description: OAK is a cutting-edge wearable device designed for the rapid treatment of anxiety and depression. The technology behind OAK has been developed in collaboration with industry-leading teams behind products like Beats, Nest, and Microsoft HoloLens.
Key Features:
- Multiple color choices
- No external wires
- Rechargeable battery
- Human voice assistant
- LED indicator light
- Waterproof
- Adjustable front and back straps
Recent Developments
Recent Developments:
- Clinical Trials and Studies: OAK has undergone a 255-subject, triple-blind, randomized, controlled trial, proving its efficacy in reducing depression within the first week of treatment. An 8-week trial for anxiety treatment was conducted by the Seattle Police Department and Washington State University, achieving its primary endpoint.
- Regulatory Approvals: Under temporary FDA clearance, the company distributed 100,000 proof-of-concept devices. They are actively engaged in obtaining full regulatory approval for OAK in the US and Europe by 2025.
- Partnerships: Fisher Wallace has partnered with the Seattle Police Department and Dr. Maurizio Fava, furthering clinical research initiatives to gain regulatory clearance.
New Products Launched: No information is available.
New Features Added to Existing Products: Fisher Wallace Labs enhanced the OAK device with features such as a human voice assistant, LED indicator light, and improved wearable comfort with adjustable straps.
New Partnerships: Fisher Wallace Labs has engaged in collaborations with top-tier design and development teams behind Beats, Nest, and Microsoft HoloLens to innovate and improve their wearable technology.
For further inquiries or information, contact Fisher Wallace Labs:
- Phone: 800.692.4380
- Fax: 800.657.7362
- Email: info@fisherwallace.com
Disclaimer: The commercialization of OAK is subject to regulatory approvals, which may require prescriptions.
